Trial Profile
Open Label 1b/2a Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2019
Price :
$35
*
At a glance
- Drugs Monalizumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Innate Pharma
- 04 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Aug 2019 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.
- 20 Apr 2018 Status changed from recruiting to active, no longer recruiting.